Given the role of impairments in the renin-angiotensin system (RAS) in the pathogenesis of hypertension and metabolic syndrome, recent research has also focussed on the potential beneficial effects of drugs targeting RAS pathway on other aspects of metabolic diseases [11]. This evidence concerns the gene REN and Other metabolic disease.